ESMO Breast Cancer Meeting

Visit us at booth No 20 and visit our presentations.

SASCIA - Oral presentation #58O
Date: Wed, 04.05.2022. Lecture time: 16:45
Session: Proffered Paper session 2
Chairs: G. Curigliano S. Delaloge S. Kim
Speakers: F. Marmé
Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment.
F. Marmé, C. Hanusch, J. Furlanetto, et al.

PenelopeB - Mini oral #60MO
Date: Tue, 03.05.2022. Lecture time: 16:22 - 16:29
Session: Mini Oral session 1
Chairs: L. Del Mastro P. Poortmans
Speakers: J. Furlanetto
Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): explorative analysis in Penelope-B
J. Furlanetto, F. Marmé, C. Thode, et al.

BMBC - Poster #170P
Date: Wed, 04.05.2022. Lecture Time: 12:15 - 13:00
Speakers: K. Riecke
Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC Registry
K. Riecke, E. Laakmann, T. Neunhöffer, et al.

GeparX - Poster #94P
Date: Wed, 04.05.2022. Lecture Time: 12:15 - 13:00
Speakers: M. Reinisch
Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)
M. Reinisch, J.-U. Blohmer, T. Link, et al.

GeparQuattro, GeparQuinto and GeparSixto - Poster #24P
Date: Wed, 04.05.2022
Lecture Time: 12:15 - 13:00
Speakers: B. Sinn
Intermediate biopsies during neoadjuvant chemotherapy for breast cancer to predict patient outcome
B. Sinn, M. Untch, T. Karn, et al.

• Visit the congress website